Change Agents Corporation CHGA

CHGA Company Overview

Avalon GloboCare Corp. is a clinical-stage biotechnology company focused on the development of cell-based therapies and immunotherapies for oncology and infectious diseases. The company operates within the biotechnology and life sciences industry, with an emphasis on leveraging cellular technologies to address unmet medical needs. Its activities are primarily research- and development-oriented, and the company has not reported significant commercial revenue from product sales, relying instead on equity financing and strategic transactions.

Founded in 2014, Avalon GloboCare initially pursued a broad immunotherapy strategy and has since evolved toward more specialized cellular therapy platforms. The company’s strategic positioning centers on integrating translational research, academic collaboration, and early-stage clinical development. Public disclosures indicate that Avalon GloboCare seeks to differentiate itself through cross-border scientific collaboration and access to novel cell therapy technologies, although several programs remain in preclinical or early clinical stages and their ultimate commercial viability is uncertain based on available public sources.